MetaCap

ADMA Biologics Inc (ADMA)

NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

13.17-0.17 (-1.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ADMA stock chart

Technical analysis

Key statistics

All statistics
52-week range
7.21 – 20.46
Day range
13.13 – 13.47
Volume / Avg
2.45M / 3.23M
Beta
—

52-week range

$7.21$20.46

ADMA stock today

On Nov 20, ADMA ended the session at $13.17, shedding $0.17 (1.27%), versus the S&P 500's 3.70% decline. Shares are 35.6% below their 52-week high of $20.46, set on Dec 12, 2025 and 82.7% above the 52-week low of $7.21, in the middle of the past year's range. ADMA is down 27.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.3%.

ADMA Biologics trades at 17.1x its trailing twelve-month earnings per share of $0.77. Its forward P/E of 14.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About ADMA Biologics

Company profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Adam S. Grossman
Headquarters
Ramsey, NJ
Employees
640

Financial highlights

Full financials

In fiscal 2025, ADMA Biologics generated $510.2 million in revenue, up 19.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $146.9 million (-25.7% year over year), for a net margin of 28.8% versus a median of -42.8% in the prior 5 years. Gross margin was 57.4% (up from 51.5%) and operating margin 37.5%.

ADMA Biologics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$510.17M$426.45M$258.21M$154.08M$80.94M
Growth+19.63%+65.15%+67.59%+90.36%+91.72%
Net income$146.93M$197.67M$-28.24M$-65.90M$-71.65M
EPS (diluted)$0.60$0.81$-0.13$-0.33$-0.51

Analyst forecast

Forecast

Consensus (4 analysts)

buy

Avg. price target

$18.00+36.67%

  • Strong buy 1
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $13.00High $22.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.22 vs $0.19
Surprise
+15.79%

ADMA news

All ADMA news

ADMA Biologics peers

Health Care sector
ADMA peer companies
CompanyPrice% ChgMarket capCompare
DNLIDenali Therapeutics Inc.18.45+1.37%$2.96Bvs ADMA
VCELVericel Corporation57.52-1.27%$2.94Bvs ADMA
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs ADMA
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs ADMA
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs ADMA
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs ADMA
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs ADMA
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs ADMA

Indexes, lists and sector

ADMA Biologics stock FAQ

What is ADMA Biologics's stock price today?

ADMA last traded at $13.17 as of Nov 20, 4:00 PM EST, down 1.27% on the day. Prices are delayed at least 15 minutes.

What is ADMA's P/E ratio?

ADMA trades at a trailing P/E ratio of 17.10 and a forward P/E of 14.06.

Who is ADMA Biologics's CEO?

Mr. Adam S. Grossman is the chief executive officer of ADMA Biologics Inc, which has about 640 employees.

What is the ADMA 52-week high?

The 52-week high for ADMA is $20.46 and the 52-week low is $7.21. The stock is currently 35.6% below its high.

Compare ADMA